Journavx, a non-opioid treatment for moderate to severe acute pain, received FDA approval with a broad label. The drug’s pricing strategy, set at a daily maintenance price of $31, has exceeded ...

Journavx, a non-opioid treatment for moderate to severe acute pain, received FDA approval with a broad label. The drug’s pricing strategy, set at a daily maintenance price of $31, has exceeded ...

Vertex has been a phenomenal growth stock, and with the FDA approval of its non-opioid pain medication Journavx in January, more growth could be on the way. The company's highly profitable ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the new Donald Trump administration. Health care stocks can often be a solid defensive play in an uncertain economy.

While the approval of Journavx (suzetrigine) has gained much positivity in non-opioid pain management, former FDA medical officer in the division of psychiatry, Josef Witt-Doerring, M.D., warns that ...

After its FDA approval in January, Journavx has garnered much attention for its potential to reshape pain management and reduce opioid reliance. Unfortunately, nearly 10% of patients initially treated ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories like pain management with its non-opioid drug Journavx. The FDA greenlit ...